Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kaketsuken (Chemo-Sero Therapeutic Research Inst.)

www.kaketsuken.or.jp/eng

Latest From Kaketsuken (Chemo-Sero Therapeutic Research Inst.)

2015 REVIEW: Japan - Corporate Rejigs, Generic Explosions, Regulatory Advances

If you missed any of our major news and analysis from Japan in 2015, here's an opportunity to check out PharmAsia News's pick of the most important stories of the year, ranging from key regulatory initiatives to company restructuring to new generic competition for local blockbusters.

BioPharmaceutical Japan

Kaketsuken Scandal Prompting Japan Regulatory Tightening

Major Japanese vaccines and blood products producer Kaketsuken is sinking ever deeper into a major manufacturing and data falsification scandal it has emerged stretches back more than 40 years, prompting discussion of official administrative sanctions and possibly criminal proceedings and moves to strengthen regulatory oversight.

BioPharmaceutical Japan

Daiichi Sankyo Builds Vaccines Business Via FluMist Deal

Daiichi Sankyo is adding to its vaccines portfolio in Japan through a deal to market in the country AstraZeneca's nasally administered quadrivalent flu product FluMist.

BioPharmaceutical Japan

Sovaldi and trelagliptin in latest Japanese approvals

Japan has approved a batch of new drugs including Gilead's Sovaldi as part of the first all-oral therapy for HCV genotype 2 in the country, Eisai's Lenvima for thyroid cancer, and the world's first once-weekly DPP-4 inhibitor from Takeda.

Metabolic Disorders Cardiovascular
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Company Type
  • Tech. Transfer Entity
  • Parent & Subsidiaries
  • Kaketsuken (Chemo-Sero Therapeutic Research Inst.)
  • Senior Management
  • Akinobu Funatsu, Dir. General
  • Contact Info
  • Kaketsuken (Chemo-Sero Therapeutic Research Inst.)
    Phone: (81) 96 344 1211
    1-6-1 Okubo
    Kumamoto-shi, 860-8568
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register